Granules India, NIPER ink pact to establish Dr Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical Development
Hyderabad: Granules India, a vertically integrated pharmaceutical company, and the esteemed National Institute of Pharmaceutical Education and Research (NIPER) in Mohali Chandigarh, have announced the signing of a Memorandum of Understanding (MOU), to establish Dr Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical Development (CCE-ISPD).
The centre will focus on crucial areas such as exploring plant-based excipients, advancements in polymer-free pharmaceutical formulations, innovative methods in producing directly compressible crystals, promotion of solvent-free pharmaceutical processes, and the development of resource-efficient and energy-efficient pharmaceutical products.
"The collaboration will feature joint research initiatives, ensuring a seamless flow of knowledge between the industry and academia. Granules India Limited has committed support for the establishment and continuous operation of the research centre. The partnership includes the establishment of state-of-the-art laboratories and research facilities within the NIPER campus to facilitate comprehensive research for development of sustainable and innovation driven pharmaceuticals. This partnership marks a significant stride in accentuating sustainability within the pharmaceutical domain, promising transformative changes for the industry and society at large globally," the release stated.
Commenting on this, Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited said, "This partnership signifies more than a collaboration; it embodies a shared vision. At Granules India, we are committed to pushing the boundaries of pharmaceutical innovation, and through this partnership with NIPER, we aim not just to make life saving medicines, but to make a difference. The CCE-ISPD is a testament to our dedication to sustainable pharmaceutical development, and we are enthusiastic about the transformative impact it will have on the industry and society."
Professor Dulal Panda, Director, NIPER, expressed his enthusiasm, "NIPER has always been at the forefront of pharmaceutical research and education. Collaborating with Granules India opens new avenues for our students and researchers to engage in real-world, impactful projects. The CCE-ISPD will be a nurturing ground for innovative ideas and sustainable solutions, shaping the future of pharmaceuticals. We are honoured to work alongside Granules India, a trailblazer in the industry, and together, we will redefine the landscape of sustainable pharmaceutical research and development."
Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered at Hyderabad. The Company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.
Read also: Granules India bags USFDA nod for Losartan and Hydrochlorothiazide Tablets
